Latest news with #RHO
Yahoo
23-06-2025
- Automotive
- Yahoo
Ford isn't going to love RAM's new warranty offering
Ford isn't going to love RAM's new warranty offering originally appeared on Autoblog. Starting with the 2026 model year, RAM is doubling down on its comeback strategy by offering something no other full-size truck brand does: a 10-year or 100,000-mile limited powertrain warranty. That's right—twice the current coverage on gas-powered RAM trucks, and a full five years longer than what Ford and GM currently offer. It's not just the half-ton RAM 1500 that's getting the extra protection. The new warranty extends to heavy-duty 2500 and 3500 models, chassis cab trucks, and even the ProMaster commercial van. Buyers of the off-road-ready Power Wagon and high-performance RHO also qualify. The only real exclusions? Fleet buyers and the all-electric ProMaster EV. That means for individual buyers, whether purchasing or leasing, this warranty could be a serious reason to reconsider a Ford F-150 or Chevy Silverado. So why the sudden move? According to RAM CEO Tim Kuniskis, the answer is simple: consumer behavior has shifted. Today's truck buyers are financing over longer terms and holding onto their vehicles longer than ever—12.6 years on average. Yet no truck brand has changed its warranty to reflect that reality. 'We think this gives people a real reason to switch,' Kuniskis said. And he's not wrong. Truck buyers are famously brand-loyal, with roughly 75–80% sticking with the same make when they buy again. But loyalty can shift if one brand clearly takes better care of its owners, especially in the long haul. Offering a longer warranty also sends a strong message: RAM believes in the durability of its new powertrains. That includes the returning 5.7-liter HEMI V-8, now offered once again as an option on the 2026 RAM 1500, and the twin-turbo Hurricane inline-six that debuted just last year. RAM is coming off a rocky year. The 2025 RAM 1500 launch hit production delays, early trims were priced too high, and removing the V-8 left a bad taste for longtime fans. But the brand is attempting to turn the page. Under new leadership, including Kuniskis' return from retirement, RAM has slashed prices, brought back the HEMI, and even announced a NASCAR comeback for 2026. The company has also rolled out a new marketing push with the tagline 'Nothing Stops RAM'. This warranty announcement isn't just a sales gimmick; it's part of a larger turnaround strategy designed to restore consumer confidence and boost conquest sales. Ford and Chevy now face a choice: match RAM's warranty or risk looking second-best in a segment where perception matters as much as specs. So far, neither has hinted at making a similar move. That leaves RAM as the sole brand offering a decade of peace of mind on core powertrain components: engine, transmission, transfer case, driveshafts, and axles. And in a world where trucks now cost as much as some luxury cars, that could be a powerful differentiator. If Ford and GM aren't worried yet, they probably should be. Ford isn't going to love RAM's new warranty offering first appeared on Autoblog on Jun 22, 2025 This story was originally reported by Autoblog on Jun 22, 2025, where it first appeared.
Miami Herald
22-06-2025
- Automotive
- Miami Herald
Ford isn't going to love RAM's new warranty offering
Starting with the 2026 model year, RAM is doubling down on its comeback strategy by offering something no other full-size truck brand does: a 10-year or 100,000-mile limited powertrain warranty. That's right-twice the current coverage on gas-powered RAM trucks, and a full five years longer than what Ford and GM currently offer. It's not just the half-ton RAM 1500 that's getting the extra protection. The new warranty extends to heavy-duty 2500 and 3500 models, chassis cab trucks, and even the ProMaster commercial van. Buyers of the off-road-ready Power Wagon and high-performance RHO also qualify. The only real exclusions? Fleet buyers and the all-electric ProMaster EV. That means for individual buyers, whether purchasing or leasing, this warranty could be a serious reason to reconsider a Ford F-150 or Chevy Silverado. So why the sudden move? According to RAM CEO Tim Kuniskis, the answer is simple: consumer behavior has shifted. Today's truck buyers are financing over longer terms and holding onto their vehicles longer than ever-12.6 years on average. Yet no truck brand has changed their warranty to reflect that reality. "We think this gives people a real reason to switch," Kuniskis said. And he's not wrong. Truck buyers are famously brand-loyal, with roughly 75–80% sticking with the same make when they buy again. But loyalty can shift if one brand clearly takes better care of its owners-especially in the long haul. Offering a longer warranty also sends a strong message: RAM believes in the durability of its new powertrains. That includes the returning 5.7-liter HEMI V-8, now offered once again as an option on the 2026 RAM 1500, and the twin-turbo Hurricane inline-six that debuted just last year. RAM is coming off a rocky year. The 2025 RAM 1500 launch hit production delays, early trims were priced too high, and removing the V-8 left a bad taste for longtime fans. But the brand is attempting to turn the page. Under new leadership, including Kuniskis' return from retirement, RAM has slashed prices, brought back the HEMI, and even announced a NASCAR comeback for 2026. The company has also rolled out a new marketing push with the tagline "Nothing Stops RAM". This warranty announcement isn't just a sales gimmick; it's part of a larger turnaround strategy designed to restore consumer confidence and boost conquest sales. Ford and Chevy now face a choice: match RAM's warranty or risk looking second-best in a segment where perception matters as much as specs. So far, neither has hinted at making a similar move. That leaves RAM as the sole brand offering a decade of peace of mind on core powertrain components: engine, transmission, transfer case, driveshafts, and axles. And in a world where trucks now cost as much as some luxury cars, that could be a powerful differentiator. If Ford and GM aren't worried yet, they probably should be. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Yahoo
10-06-2025
- Business
- Yahoo
argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease
ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in autoantibodies and improved functional outcomes in patients with Sjogren's disease; program granted U.S. FDA Fast Track designation argenx committed to new therapeutic areas in rheumatology with ongoing Phase 3 studies in myositis (ALKIVIA) and Sjogren's disease (UNITY) June 11, 2025, 12:01 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of positive results from Phase 2 studies evaluating VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) in Sjogren's disease (SjD) and idiopathic inflammatory myopathies (IIM or myositis) at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the U.S. Food and Drug Administration (FDA) has granted efgartigimod Fast Track designation (FTD) for the treatment of primary Sjogren's disease. 'Our innovation model prioritizes strong biologic rationale and efficient clinical program design, which enables us to rapidly advance development in rheumatic diseases,' said Luc Truyen, M.D., Ph.D., Chief Medical Officer, argenx. 'The accumulating body of evidence about the role of IgG autoantibodies reinforces the therapeutic potential of efgartigimod as a new approach for treating several rheumatic diseases – aiming to go beyond symptom management by targeting the underlying disease. The data presented at EULAR highlight efgartigimod's potential as a precision therapy for patients living with myositis and Sjogren's disease, and we are hopeful this novel treatment will offer a new therapeutic option and lead to improved outcomes for patients.' ALKIVIA Data Show Efgartigimod Provides Functional Improvement in Patients with Myositis Consistent and statistically significant treatment effect: In the ongoing, seamless ALKIVIA Phase 2/3 study evaluating three myositis subtypes (IMNM, ASyS, DM), data from Phase 2 show that patients demonstrated significant improvement in muscle strength and physical function when treated with efgartigimod. The study's primary endpoint, mean Total Improvement Score (TIS) at 24 weeks, is a composite of six core measures of disease activity and muscle function. TIS improvement was observed in a majority of efgartigimod-treated patients across all six core measures, and the primary endpoint was met. Efgartigimod patients showed a significantly higher mean TIS of 50.45 compared to 35.65 in the placebo arm (2-sided P=0.0004). In addition, for patients treated with efgartigimod, 79% achieved a moderate improvement (TIS ≥40) and 34% achieved a major improvement (TIS ≥60), compared to 47% and 9.5% respectively of patients receiving placebo. Favorable Time to TIS and Safety Profile: Among the study's secondary endpoints, patients receiving efgartigimod improved significantly faster than patients receiving placebo, leading to a median time to minimal improvement (TIS ≥20) of 30 days and time to moderate improvement (TIS ≥40) of 16 weeks. Comparatively, patients in the placebo arm reached minimal improvement (TIS ≥20) in 72 days, while there was no majority of placebo patients reaching moderate improvement (TIS ≥40) at any point in the 24-week study. Efgartigimod was well-tolerated and the proportion of patients experiencing at least one treatment-emergent adverse event (TEAE) was similar in the efgartigimod and placebo arms. Evaluation of efgartigimod in myositis is ongoing in the Phase 3 portion of the ALKIVIA study. 'Myositis is a debilitating disease that can cause muscle weakness, affect multiple organs, and have a severe impact on patients' quality of life. Physicians struggle to treat it because current options are limited and have significant side effects,' said Hector Chinoy, Ph.D., ALKIVIA study investigator and Professor of Rheumatology and Neuromuscular Disease at The University of Manchester. 'Results from this study, the first of an FcRn inhibitor in myositis, demonstrate the potential of a transformative targeted treatment approach. Efgartigimod was well-tolerated and led to significant improvements compared to placebo, offering new hope for a treatment that targets autoantibodies as one of the potential key drivers of disease.' RHO Data Show Efgartigimod's Clinical Effect Across Endpoints in Sjogren's Disease Improved systemic disease activity and reduction in symptoms: In the Phase 2 proof-of-concept RHO study, efgartigimod showed significant improvement in systemic disease activity and patient symptoms. 45.5% of patients receiving efgartigimod achieved improved outcomes on the CRESS composite primary endpoint at Week 24 – including systemic disease activity, salivary and tear gland function – compared to 11.1% among patients treated with placebo. Improvements among patients treated with efgartigimod were achieved in 4 out of 5 CRESS measures. In addition, disease activity among patients treated with efgartigimod showed a median change in clinESSDAI total score of -7.0 versus -4.0 in the placebo arm. A key secondary endpoint is the cSTAR composite of five disease measures, which showed patients treated with efgartigimod achieved a 54.5% response versus 33.3% in the placebo arm. Potential for disease biology modulation: Biomarker response in RHO study also demonstrated rapid and sustained reduction of IgG with a ~60% reduction from Week 4 onwards. The efgartigimod group showed notable decreases in the disease-associated antibodies anti-Ro52 (-57% vs +13%) and Rheumatoid Factor (-26.6% vs -5.3%), as well as reduction in C1Q immune complexes (-4.5 vs -0.06 mc eq/mL) compared to placebo. Efgartigimod demonstrated a favorable safety profile among patients with Sjogren's disease. The observed safety and tolerability was consistent with other clinical trials, with no new safety signals observed. The Phase 3 UNITY trial is currently ongoing to assess efficacy and safety of efgartigimod in patients with moderate to severe Sjogren's disease. 'These data suggest that targeting FcRn and reducing IgGs has a meaningful impact on Sjogren's disease,' said Isabelle Peene M.D., Ph.D., study investigator, Department of Rheumatology, Ghent University Hospital. 'The clinical and biomarker findings add to our growing understanding of IgG autoantibodies in Sjogren's disease and could inform future treatment strategies for this complex, progressive and underserved condition.' More information on the data presented at the EULAR 2025 meeting can be found for presentations are as follows: Title Presenter Presentation Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy: Phase 2 Results from the ALKIVIA Study Hector Chinoy Oral Presentation #OP0002Session: Abstract PlenaryWednesday, June 1116:40-16:50 CEST Treatment of Sjögren's disease by blocking FcRn: clinical and translational data from Rho, a phase 2 randomized, placebo controlled, double-blind, proof-of-concept study with efgartigimod Isabelle Peene Oral Presentation #OP0041Session: Clinical AbstractWednesday, June 1116:30-16:40 CEST Efficacy and safety of efgartigimod PH20 subcutaneous by prefilled syringe in adults with Sjögren's disease: A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial with open-label extension (UNITY) Simon Bowman Poster #POS0844Poster View IIIThursday, June 1212:00-13:30 CEST Safety, tolerability, and efficacy of empasiprubart in adults with dermatomyositis (EMPACIFIC): A Phase 2, randomized, double-blind, placebo-controlled, multicenter study Tetyana Storie Poster #POS1049Poster View VIFriday, June 1312:00-13:30 CEST ALKIVIA Study DesignThe ALKIVIA study is a randomized, double-blind, placebo-controlled, multicenter, operationally seamless Phase 2/3 study of efgartigimod SC for the treatment of idiopathic inflammatory myopathies (IIM or myositis) across three subtypes, including immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM). The ALKIVIA study enrolled 240 patients in total and is being conducted in two phases, with an analysis of the Phase 2 portion of the clinical trial after the first 90 patients completed the study, followed by a Phase 3 portion if a signal is observed in the Phase 2 portion. The primary endpoint is the mean total improvement score (TIS) at the end of the treatment period (24 weeks in Phase 2 and 52 weeks in Phase 3) of all treated patients (IMNM, ASyS, DM) compared to placebo. Key secondary endpoints include response rates at the end of treatment, time to response, and duration of response in TIS, as well as change from baseline in individual TIS components. Other secondary endpoints include quality of life and other functional scores. About Idiopathic Inflammatory MyopathiesIdiopathic inflammatory myopathies (myositis) are a rare group of autoimmune diseases that can be muscle specific or affect multiple organs including the skin, joints, lungs, gastrointestinal tract and heart. Myositis can be very severe and disabling and have a material impact on quality of life. Initially, myositis was classified as either DM or polymyositis, but as the underlying pathophysiology of myositis has become better understood, including through the identification of characteristic autoantibodies, new polymyositis subtypes have emerged. Two of these subtypes are IMNM and ASyS. Proximal muscle weakness is a unifying feature of each subtype. IMNM is characterized by skeletal muscle weakness due to muscle cell necrosis. ASyS is characterized by muscle inflammation, inflammatory arthritis, interstitial lung disease, thickening and cracking of the hands ('mechanic's hands') and Raynaud's phenomenon. DM is characterized by muscle inflammation and degeneration and skin abnormalities, including heliotrope rash, Gottron's papules, erythematous, calcinosis and edema. RHO Study DesignThe Phase 2 RHO study was a randomized, double-blinded, placebo-controlled multicenter proof of concept study to evaluate the safety and efficacy of efgartigimod in adults with Sjogren's Disease. In order to enter the study, patients needed to test positive for anti-Ro autoantibodies and maintain residual salivary flow. Thirty four patients were randomized 2:1 to receive either efgartigimod or placebo for up to 24 weeks. Multiple endpoints and biomarkers were evaluated in the signal-finding study, including the primary endpoint of CRESS (Composite of Relevant Endpoints for Sjogren's Syndrome). Within CRESS there are five components spanning: systemic disease activity as measured by the ESSDAI (EULAR Sjogren's Syndrome Activity Index), patient reported outcomes as measured by the ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index), tear and salivary gland function and serology. To be a CRESS responder, patients needed to demonstrate a clinically meaningful benefit in at least 3 of the 5 composite items. Additional datapoints were gathered including the clinESSDAI, STAR (Sjogren's Tool for Assessing Response), biomarker data, and the change in lymphocytic infiltrate levels through parotid biopsies. About Sjogren's DiseaseSjogren's Disease (SjD) is a chronic, slowly progressive inflammatory systemic autoimmune disease characterized by immune-mediated destruction of exocrine glands. SjD can be severely debilitating and have a negative impact on patient quality of life, with common symptoms reported as dry eyes and mouth, fatigue, and joint point. In addition, a substantial subset of patients suffer from extraglandular systemic disease. While the presence of anti-Ro and anti-La IgG autoantibodies are considered a hallmark of disease, the underlying cause of SjD is believed to be multi-factorial, triggered by environmental factors, leading to autoimmunity and chronic inflammation. SjD predominantly impacts women with a 9:1 female:male incidence ratio. Given the heterogeneous nature of the disease, the treatment journey can be challenging with long delays and high rates of misdiagnosis. There are no FDA- approved treatments targeting the disease itself, leaving current treatments to focus primarily on individual symptom management. About EfgartigimodEfgartigimod (efgartigimod alfa and hyaluronidase-qvfc) is a human IgG1 antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor (FcRn) and blocking the IgG recycling process. Efgartigimod is the first-approved FcRn blocker globally and is marketed as VYVGART® and VYVGART® Hytrulo in the United States and China for the treatment of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), and as VYVDURA (Japan) or VYVGART SC for gMG in other regions globally. Efgartigimod is currently being evaluated in more than 15 severe autoimmune diseases where pathogenic IgGs are believed to be mediators of disease. About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. For further information, please contact: Media: Colin McBeancmcbean@ Investors: Alexandra Royaroy@ Forward-looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aim,' 'are,' 'believe,' 'can,' 'commit,' and 'will' and include statements argenx makes concerning its commitment to improving the lives of people suffering from severe autoimmune diseases and to new therapeutic areas in rheumatology; the discussion of its Phase 2 proof-of-concept results as well as the ongoing Phase 3 studies for efgartigimod in myositis and Sjogren's disease at EULAR 2025, including the planned agenda of such congress; its ability to rapidly advance development in rheumatic diseases; its goal to have efgartigimod not just manage symptoms but target the underlying disease and its potential as a precision therapy for myositis and Sjogren's patients; the potential for efgartigimod to be a transformative targeted treatment approach; and its hope that efgartigimod leads to improved outcomes and offer a new therapeutic options for such patients. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Drive
05-06-2025
- Automotive
- The Drive
Ram Won't Say ‘No' to Hemi V8-Powered RHO
The latest car news, reviews, and features. We know the Hemi V8-powered Ram 1500 is officially coming back, there's one big question: What about the RHO? It's the brand's Ford F-150 Raptor fighter that currently uses a high-output Hurricane I6 engine, and while a naturally aspirated V8 version might not be faster , some might argue that it would be better . The Drive asked Ram CEO Tim Kuniskis if a Hemi RHO is in the cards. 'I don't know,' he admitted. 'We've debated that a lot internally.' The RHO's twin-turbo 3.0-liter inline-six may not be what people are used to, but it is stout. Engine output measures 540 horsepower and 521 lb-ft of torque. It has lots of upgraded parts compared to the standard-output Hurricane, like all-forged internals and 26 pounds of boost versus the S.O.'s 22 psi. Kuniskis rightfully worries that a naturally aspirated V8 making 395 hp and 410 lb-ft of torque might not be enough. 'I drive an RHO now, and it is a fantastic package,' Kuniskis continued. 'If you put a 5.7-liter in it, compared to what it is today, is that going to meet customer expectations? That's what we're thinking about right now.' 'Not saying we won't do it, but that's what we're thinking about right now.' Ram Stellantis People can't seem to talk about the RHO without mentioning the old Ram TRX and its supercharged Hellcat V8. That's understandable, considering they look similar and share Baja-blasting credentials like semi-active Bilstein suspension and 35-inch tires. If Ram does end up tossing the 5.7-liter into the RHO, it might sound slightly more like the TRX, but it will be a far cry from the infamously discontinued truck's 707 hp. The idea of a 5.7-liter Hemi-powered RHO would be more like a first-gen Raptor than anything since that pickup went away. It would provide a V8 soundtrack rather than the Hurricane I6's weakened battle cry while being magnitudes less complex, and not to mention more balanced than the TRX. Simpler times when not everything needed ridiculous horsepower. Maybe I'm getting ahead of myself. Either way, Ram won't say 'no' to a V8 RHO just yet. Got a tip or question for the author? Contact them directly: caleb@
Campaign ME
09-05-2025
- Automotive
- Campaign ME
RAM launches the world's shortest flight ‘RHO Airlines'
RAM Trucks has taken to the skies – briefly – to launch its latest performance vehicle with a bold and unexpected activation. In partnership with Publicis Middle East, the brand unveiled 'RHO Airlines', a creative stunt that turned the desert into a runway for what is being described as the world's shortest flight, lasting just 1.2 seconds. To bring the idea to life, RAM and Publicis built a fully immersive airport experience in the middle of the desert, complete with check-in counters, security, ground staff, air traffic control and cabin crew. The only thing missing was a plane. Instead, at the centre of the experience was the new RAM RHO 1500, a high-performance truck engineered for speed, agility and off-road capability. The activation featured Saudi Arabia's popular duo The Saudi Reporters in what the brand calls a 'first-of-its-kind' influencer stunt. One brother, Abdullah, pranked the other, Abdulaziz, into thinking he was boarding a new desert-based airline. Instead, he found himself in the passenger seat of the RHO 1500 as it launched off a sand dune – piloted by a professional stunt driver. 'This stunt captures the essence of RAM. It is about power, capability and the spirit of adventure,' said Stuart Laurie, Head of RAM Brand at Stellantis Middle East. 'The RAM RHO 1500 is not just built to conquer roads and terrains. It is engineered to push boundaries and fire up imaginations, which is exactly what RHO Airlines brings to life.' The campaign kicked off with teaser content across RAM's social platforms, hinting at the arrival of a mysterious new airline. The full reveal came through a hero video that documented the prank and airborne moment in a fast-paced, cinematic format. 'The RHO is unexpectedly thrilling to drive, and we wanted to create an experience that was equally unexpected,' added Tuki Ghiassi, Executive Creative Director at Publicis Middle East. 'RHO Airlines is what happens when you take a product truth and turn it into a full-blown experience.' The activation marks the first phase of a wider brand campaign, with additional content expected to roll out in the coming weeks.
